What is he best known for?
The fields of study he is best known for:
Shantu Amin mainly focuses on Biochemistry, Carcinogen, Pharmacology, Carcinogenesis and Nitrosamine.
His Carcinogen study combines topics from a wide range of disciplines, such as Endocrinology, Chrysene, Pyrene and Internal medicine.
His Pharmacology research incorporates elements of Chemotherapy and Tumor initiation.
His Carcinogenesis study deals with Cancer research intersecting with Cancer cell, Metastasis and Cell culture.
His studies in Nitrosamine integrate themes in fields like Corn oil, Pathology, Lung and Ratón.
His research in Benzopyrene focuses on subjects like DNA repair, which are connected to Stereochemistry, Oligonucleotide and Base pair.
His most cited work include:
- Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1 (720 citations)
- Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. (335 citations)
- Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease (329 citations)
What are the main themes of his work throughout his whole career to date?
Shantu Amin mainly investigates Carcinogen, Biochemistry, Stereochemistry, Cancer research and DNA.
His Carcinogen study combines topics in areas such as Carcinogenesis, Molecular biology, Endocrinology and Internal medicine.
As part of one scientific family, Shantu Amin deals mainly with the area of Biochemistry, narrowing it down to issues related to the Pharmacology, and often Microsome.
His Stereochemistry study incorporates themes from Epoxide, Chrysene, Pyrene, Adduct and Diol.
He interconnects Apoptosis, Cancer, Immunology and Cell growth in the investigation of issues within Cancer research.
His work carried out in the field of Nitrosamine brings together such families of science as Toxicity and Ratón.
He most often published in these fields:
- Carcinogen (31.22%)
- Biochemistry (29.76%)
- Stereochemistry (22.32%)
What were the highlights of his more recent work (between 2013-2021)?
- Cancer research (23.96%)
- Cancer (13.07%)
- Apoptosis (12.89%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Cancer, Apoptosis, Biochemistry and Cancer cell.
His study in Cancer research is interdisciplinary in nature, drawing from both Carcinogenesis, Cell culture, STAT3 and Stem cell.
His Cancer research integrates issues from Immunology, Kinase, Pharmacology and Survival rate.
His work is connected to Carcinogen, DNA adduct, DNA, Deoxyadenosine and Benzopyrene, as a part of Biochemistry.
Shantu Amin combines subjects such as Molecular biology, Toxicology, Ovary and Chrysene with his study of Carcinogen.
While the research belongs to areas of DNA, Shantu Amin spends his time largely on the problem of Adduct, intersecting his research to questions surrounding Guanine and Pyrene.
Between 2013 and 2021, his most popular works were:
- Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease (329 citations)
- Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. (254 citations)
- Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. (158 citations)
In his most recent research, the most cited papers focused on:
His scientific interests lie mostly in Biochemistry, Cancer research, Aryl hydrocarbon receptor, Signal transduction and Cell biology.
Biochemistry and In vivo are commonly linked in his work.
The various areas that Shantu Amin examines in his Cancer research study include Cell culture, Endocrinology, Cancer and Apoptosis.
His biological study spans a wide range of topics, including Cancer cell, Suppressor and CYP1B1.
His DNA repair research includes themes of Mouth neoplasm and Carcinogen.
His research links Epoxide with Carcinogen.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
